版本:
中国

BRIEF-TESARO announces availability of ovarian cancer drug in U.S.

April 19 TESARO Inc-

* TESARO announces availability of zejula™ (niraparib) for patients with recurrent ovarian cancer in the U.S.

* Tesaro inc says wholesale acquisition cost of zejula is $9,833 for a one-month supply of zejula at a dose of 200 milligrams once per day Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐